Moderna (NASDAQ: MRNA) saw its stock rise 5.5% after the FDA indicated it would accept the company’s application for a new seasonal flu vaccine for the 2026-2027 season, reversing a prior rejection due to insufficient safety testing. The FDA’s change in stance comes as Moderna commits to additional testing to ensure the vaccine’s safety for elderly patients. This development marks a significant step forward for the company in the vaccine market. Image source: Getty Images.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
